Antonis Fanouriakis

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 63

Top Topics

Interstitial Lung Disease

Disease Activity

Systemic Lupus Erythematosus

Top Venues

Annals of the rheumatic diseases

Lupus science & medicine

Rheumatology (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Maria P Yavropoulou, Maria G Filippa, Nikolaos I Vlachogiannis, George E Fragoulis, Katerina Laskari, Aimilia Mantzou, Stylianos Panopoulos, Antonis Fanouriakis, Vassiliki-Kalliopi Bournia, Gerasimos Evangelatos, Aggeliki Papapanagiotou, Maria G G Tektonidou, George P Chrousos, Petros P Sfikakis
Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study. RMD open 10 (1) (2024)
Myrto Kostopoulou, Chetan B Mukhtyar, George K Bertsias, Dimitrios T Boumpas, Antonis Fanouriakis
Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations. Annals of the rheumatic diseases (2024)
Maria P Yavropoulou, Maria G Filippa, Nikolaos I Vlachogiannis, George E Fragoulis, Katerina Laskari, Aimilia Mantzou, Stylianos Panopoulos, Antonis Fanouriakis, Vassiliki-Kalliopi Bournia, Gerasimos Evangelatos, Aggeliki Papapanagiotou, Maria G G Tektonidou, George P Chrousos, Petros P Sfikakis
Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study. RMD open 10 (1) (2024)
Maria P Yavropoulou, Maria G Filippa, Nikolaos I Vlachogiannis, George E Fragoulis, Katerina Laskari, Aimilia Mantzou, Stylianos Panopoulos, Antonis Fanouriakis, Vassiliki-Kalliopi Bournia, Gerasimos Evangelatos, Aggeliki Papapanagiotou, Maria G G Tektonidou, George P Chrousos, Petros P Sfikakis
Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study. RMD open 10 (1) (2024)
Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Antonio Marangoni, Irini Flouri, Nestor Avgoustidis, Konstantinos Parperis, Antonis Fanouriakis, Marcello Govoni, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alessandra Bortoluzzi, George K Bertsias
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the rheumatic diseases 83 (4) (2024)
Dionysis S Nikolopoulos, Catherine Loukogiannaki, George Sentis, Panagiotis Garantziotis, Theodora Manolakou, Noemin Kapsala, Myrto Nikoloudaki, Antigone Pieta, Sofia Flouda, Ioannis Parodis, George K Bertsias, Antonis Fanouriakis, Anastasia Filia, Dimitrios T Boumpas
Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events. Annals of the rheumatic diseases (2024)
Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Antonio Marangoni, Irini Flouri, Nestor Avgoustidis, Konstantinos Parperis, Antonis Fanouriakis, Marcello Govoni, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alessandra Bortoluzzi, George K Bertsias
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the rheumatic diseases 83 (4) (2024)
Maria Pappa, Maria Kosmetatou, Antigone Pieta, Myrto Nikoloudaki, Nektarios Marios Liapis, Christina Tsalapaki, Aglaia Chalkia, Evangelia Argyriou, Theodoros Dimitroulas, Myrto Cheila, Georgios Demirtzoglou, Charalampos Papagoras, Andreas Goules, Christina Katsiari, Dimitrios Vassilopoulos, Prodromos Sidiropoulos, Kyriaki A Boki, Petros P Sfikakis, George Liapis, Harikleia Gakiopoulou, Paraskevi Vasileios Voulgari, Dimitrios T Boumpas, George K Bertsias, Maria G G Tektonidou, Antonis Fanouriakis
Attainment of EULAR/ERA-EDTA targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study. RMD open 10 (3) (2024)
Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Antonio Marangoni, Irini Flouri, Nestor Avgoustidis, Konstantinos Parperis, Antonis Fanouriakis, Marcello Govoni, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alessandra Bortoluzzi, George K Bertsias
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the rheumatic diseases 83 (4) (2024)
Antonis Fanouriakis, George K Bertsias, Dimitrios T Boumpas
Response to: Correspondence on 'EULAR recommendations for the management of systemic lupus erythematosus: 2023 update' by Fanouriakis et al . Annals of the rheumatic diseases (2024)
Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Antonio Marangoni, Irini Flouri, Nestor Avgoustidis, Konstantinos Parperis, Antonis Fanouriakis, Marcello Govoni, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alessandra Bortoluzzi, George K Bertsias
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the rheumatic diseases (2024)
Sofia Flouda, Evgenia Emmanouilidou, Anastasios Karamanakos, Dimitra Koumaki, Dimitrios Katsifis-Nezis, Argyro Repa, George K Bertsias, Dimitrios Boumpas, Antonis Fanouriakis
Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: A case series of 18 patients. Lupus (2024)
Maria P Yavropoulou, Maria G Filippa, Nikolaos I Vlachogiannis, George E Fragoulis, Katerina Laskari, Aimilia Mantzou, Stylianos Panopoulos, Antonis Fanouriakis, Vassiliki-Kalliopi Bournia, Gerasimos Evangelatos, Aggeliki Papapanagiotou, Maria G G Tektonidou, George P Chrousos, Petros P Sfikakis
Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study. RMD open 10 (1) (2024)
Antonis Fanouriakis, Myrto Kostopoulou, George K Bertsias, Dimitrios T Boumpas
Response to: Correspondence on 'EULAR recommendations for the management of systemic lupus erythematosus: 2023 update' by Fanouriakis et al . Annals of the rheumatic diseases (2024)
Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Antonio Marangoni, Irini Flouri, Nestor Avgoustidis, Konstantinos Parperis, Antonis Fanouriakis, Marcello Govoni, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alessandra Bortoluzzi, George K Bertsias
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the rheumatic diseases 83 (4) (2024)
Dionysis S Nikolopoulos, Catherine Loukogiannaki, George Sentis, Panagiotis Garantziotis, Theodora Manolakou, Noemin Kapsala, Myrto Nikoloudaki, Antigone Pieta, Sofia Flouda, Ioannis Parodis, George K Bertsias, Antonis Fanouriakis, Anastasia Filia, Dimitrios T Boumpas
Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events. Annals of the rheumatic diseases 83 (9) (2024)
Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Antonio Marangoni, Irini Flouri, Nestor Avgoustidis, Konstantinos Parperis, Antonis Fanouriakis, Marcello Govoni, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alessandra Bortoluzzi, George K Bertsias
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the rheumatic diseases 83 (4) (2024)
Spyridon Katechis, Dionysis S Nikolopoulos, Sofia Flouda, Christina Adamichou, Katerina Chavatza, Noemin Kapsala, Pelagia Katsimbri, George K Bertsias, Dimitrios T Boumpas, Antonis Fanouriakis
Can we predict kidney involvement in patients with systemic lupus erythematosus? A retrospective cohort study with independent validation. Rheumatology (Oxford, England) (2024)
Binod Neupane, Pragya Shukla, Mahmoud Slim, Amber Martin, Michelle A Petri, George K Bertsias, Alfred H J Kim, Antonis Fanouriakis, Roger Abramino Levy, Deven Chauhan, Nick Ballew
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks. Lupus science & medicine 10 (1) (2023)
Binod Neupane, Pragya Shukla, Mahmoud Slim, Amber Martin, Michelle A Petri, George K Bertsias, Alfred H J Kim, Antonis Fanouriakis, Roger Abramino Levy, Deven Chauhan, Nick Ballew
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks. Lupus science & medicine 10 (1) (2023)
Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, Martin Aringer, Laurent Arnaud, Sang-Cheol Bae, John Boletis, Ian N Bruce, Ricard Cervera, Andrea Doria, Thomas Dörner, Richard A Furie, Dafna D Gladman, Frederic A Houssiau, Luís Sousa Inês, David R W Jayne, Marios Kouloumas, László Kovács, Chi Chiu Mok, Eric F Morand, Gabriella Moroni, Marta Mosca, Johanna Mucke, Chetan B Mukhtyar, György Nagy, Sandra Navarra, Ioannis Parodis, José M Pego-Reigosa, Michelle A Petri, Bernardo A Pons-Estel, Matthias Schneider, Josef S Smolen, Elisabet Svenungsson, Yoshiya Tanaka, Maria G G Tektonidou, Y K Onno Teng, Angela Tincani, Edward M Vital, Ronald F Van Vollenhoven, Chris Wincup, George K Bertsias, Dimitrios T Boumpas
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the rheumatic diseases (2023)
Myrto Kostopoulou, Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas
Annals of the Rheumatic Diseases collection on lupus nephritis (2019-2022): novel insights and advances in therapy. Annals of the rheumatic diseases (2023)
Myrto Kostopoulou, Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas
Annals of the Rheumatic Diseases collection on lupus nephritis (2019-2022): novel insights and advances in therapy. Annals of the rheumatic diseases (2023)
Binod Neupane, Pragya Shukla, Mahmoud Slim, Amber Martin, Michelle A Petri, George K Bertsias, Alfred H J Kim, Antonis Fanouriakis, Roger Abramino Levy, Deven Chauhan, Nick Ballew
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks. Lupus science & medicine 10 (1) (2023)
Myrto Kostopoulou, Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas
Annals of the Rheumatic Diseases collection on lupus nephritis (2019-2022): novel insights and advances in therapy. Annals of the rheumatic diseases 82 (6) (2023)
Antonis Fanouriakis, George K Bertsias, George Liapis, Smaragdi Marinaki, Aikaterini Papagianni, Maria Stangou, Alexandros Garyfallos, Sophia Lionaki, Maria G G Tektonidou, John N Boletis, Dimitrios T Boumpas
Multidisciplinary approach to lupus nephritis: Clinical pearls, pitfalls, and positioning of newly-approved agents. Lupus (2023)
Binod Neupane, Pragya Shukla, Mahmoud Slim, Amber Martin, Michelle A Petri, George K Bertsias, Alfred H J Kim, Antonis Fanouriakis, Roger Abramino Levy, Deven Chauhan, Nick Ballew
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks. Lupus science & medicine 10 (1) (2023)
Myrto Kostopoulou, Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas
Annals of the Rheumatic Diseases collection on lupus nephritis (2019-2022): novel insights and advances in therapy. Annals of the rheumatic diseases 82 (6) (2023)
Myrto Kostopoulou, Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas
Annals of the Rheumatic Diseases collection on lupus nephritis (2019-2022): novel insights and advances in therapy. Annals of the rheumatic diseases (2023)
Binod Neupane, Pragya Shukla, Mahmoud Slim, Amber Martin, Michelle A Petri, George K Bertsias, Alfred H J Kim, Antonis Fanouriakis, Roger Abramino Levy, Deven Chauhan, Nick Ballew
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks. Lupus science & medicine 10 (1) (2023)
Myrto Kostopoulou, Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas
Annals of the Rheumatic Diseases collection on lupus nephritis (2019-2022): novel insights and advances in therapy. Annals of the rheumatic diseases 82 (6) (2023)
Maria Pappa, Alexandros Panagiotopoulos, Konstantinos Thomas, Antonis Fanouriakis
Systemic Lupus Erythematosus and COVID-19. Current rheumatology reports (2023)
Myrto Kostopoulou, Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas
Annals of the Rheumatic Diseases collection on lupus nephritis (2019-2022): novel insights and advances in therapy. Annals of the rheumatic diseases 82 (6) (2023)
George E Fragoulis, Anastasios Karamanakos, Aikaterini Arida, Vassiliki-Kalliopi Bournia, Gerasimos Evangelatos, Antonis Fanouriakis, Kalliopi Fragiadaki, Evrydiki Kravvariti, Katerina Laskari, Stylianos Panopoulos, Nikolaos Papazoglou, Maria Pappa, Maria G G Tektonidou, Petros P Sfikakis
Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases. RMD open 8 (1) (2022)
Abdulsamet Erden, Hakan Apaydın, Antonis Fanouriakis, Serdar Can Güven, Berkan Armagan, Pınar Akyüz Dağlı, Hatice Ecem Konak, Bünyamin Polat, Ebru Atalar, Serdar Esmer, Özlem Karakaş, Bahar Özdemir, Mehmet Akif Eksin, Ahmet Omma, Orhan Kücüksahin, George K Bertsias, Dimitrios T Boumpas
Performance of the systemic lupus erythematosus risk probability index in a cohort of undifferentiated connective tissue disease. Rheumatology (Oxford, England) 61 (9) (2022)
Dionysis S Nikolopoulos, Lampros Fotis, Ourania Gioti, Antonis Fanouriakis
Tailored treatment strategies and future directions in systemic lupus erythematosus. Rheumatology international 42 (8) (2022)
Myrto Kostopoulou, Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas
Treatment of lupus: more options after a long wait. Annals of the rheumatic diseases 81 (6) (2022)
Anastasios Karmanakos, Gerasimos Evangelatos, Maria Pappa, Kalliopi Fragiadaki, Antonis Fanouriakis, George E Fragoulis
Chilblains After SARS-CoV-2 Vaccination: Coincidence or Real Association? The Journal of rheumatology 49 (11) (2022)
Eleni Frangou, Panagiotis Garantziotis, Maria Grigoriou, Aggelos Banos, Dionysis S Nikolopoulos, Antigone Pieta, Stavros A Doumas, Antonis Fanouriakis, Aikaterini Hatzioannou, Theodora Manolakou, Themis Alissafi, Panayotis Verginis, Emmanouil Athanasiadis, Emmanouil Dermitzakis, George Bertsias, Anastasia Filia, Dimitrios T Boumpas
Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis. Annals of the rheumatic diseases 81 (10) (2022)
Theodora Manolakou, Dionysis S Nikolopoulos, Dimitrios Gkikas, Anastasia Filia, Martina K Samiotaki, George M Stamatakis, Antonis Fanouriakis, Panagiotis Politis, Aggelos Banos, Themis Alissafi, Panayotis Verginis, Dimitrios T Boumpas
ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus. Science advances 8 (43) (2022)
Katerina Chavatza, Myrto Kostopoulou, Dionysis S Nikolopoulos, Ourania Gioti, Konstantina Togia, Laura Andreoli, Martin Aringer, John Boletis, Andrea Doria, Frederic A Houssiau, David Jayne, Marta Mosca, Elisabet Svenungsson, Angela Tincani, George Bertsias, Antonis Fanouriakis, Dimitrios T Boumpas
Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. Annals of the rheumatic diseases 80 (9) (2021)
Despina Antypa, Nicholas J Simos, Eleftherios Kavroulakis, George Bertsias, Antonis Fanouriakis, Prodromos Sidiropoulos, Dimitrios Boumpas, Efrosini Papadaki
Anxiety and depression severity in neuropsychiatric SLE are associated with perfusion and functional connectivity changes of the frontolimbic neural circuit: a resting-state f(unctional) MRI study. Lupus science & medicine 8 (1) (2021)
Antonis Fanouriakis, Nikolaos Tziolos, George Bertsias, Dimitrios T Boumpas
Response to: Correspondence on "Update on the diagnosis and management of systemic lupus erythematosus" by Fanouriakis et al. Annals of the rheumatic diseases (2021)
Christina Adamichou, Irini Genitsaridi, Dionysis S Nikolopoulos, Myrto Nikoloudaki, Argyro Repa, Alessandra Bortoluzzi, Antonis Fanouriakis, Prodromos Sidiropoulos, Dimitrios T Boumpas, George K Bertsias
Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. Annals of the rheumatic diseases (2021)
Dionysis S Nikolopoulos, Myrto Kostopoulou, Antigoni Pieta, Sofia Flouda, Katerina Chavatza, Aggelos Banos, John Boletis, Pelagia Katsimbri, Dimitrios T Boumpas, Antonis Fanouriakis
Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease. Lupus science & medicine 7 (1) (2021)
Antonis Fanouriakis, Argyro Lazarini, Ioannis Sofianos, Constantinos Papadopoulos, Eleni Bagiazidou, Alexia Balanika, Antonia Elezoglou
Diffuse oesophageal involvement in anti-NXP2 myositis and response to combined immunosuppressive therapy. Rheumatology (Oxford, England) 60 (11) (2021)
Myrto Kostopoulou, Antonis Fanouriakis, Kim Cheema, John Boletis, George Bertsias, David Jayne, Dimitrios T Boumpas
Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. RMD open 6 (2) (2021)
Dionysis S Nikolopoulos, Antonis Fanouriakis, George K Bertsias
Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives. Expert review of clinical immunology 17 (4) (2021)
Kalliopi Klavdianou, Argyro Lazarini, Antonis Fanouriakis
Targeted Biologic Therapy for Systemic Lupus Erythematosus: Emerging Pathways and Drug Pipeline. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 34 (2) (2021)
Dionysis S Nikolopoulos, Dimitris Kitsos, Matilda Papathanasiou, Maria Chondrogianni, Aikaterini Theodorou, Panagiotis Garantziotis, Antigone Pieta, Triantafyllos Doskas, George K Bertsias, Konstantinos Voumvourakis, Dimitrios T Boumpas, Antonis Fanouriakis
Demyelination with autoimmune features: a distinct clinical entity? Results from a longitudinal cohort. Rheumatology (Oxford, England) 60 (9) (2021)
Antonis Fanouriakis, Myrto Kostopoulou, Kim Cheema, Hans-Joachim Anders, Martin Aringer, Ingeborg Bajema, John Boletis, Eleni Frangou, Frederic A Houssiau, Jane Hollis, Adexandre Karras, Francesca Marchiori, Stephen D Marks, Gabriella Moroni, Marta Mosca, Ioannis Parodis, Manuel Praga, Matthias Schneider, Josef S Smolen, Vladimir Tesar, Maria Trachana, Ronald F Van Vollenhoven, Alexandre E Voskuyl, Y K Onno Teng, Bernadette van Leew, George Bertsias, David Jayne, Dimitrios T Boumpas
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Annals of the rheumatic diseases 79 (6) (2020)
Antonis Fanouriakis, Nikolaos Tziolos, George K Bertsias, Dimitrios T Boumpas
Update οn the diagnosis and management of systemic lupus erythematosus. Annals of the rheumatic diseases 80 (1) (2020)
Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas
Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or 'blood-dominant' lupus? Annals of the rheumatic diseases 79 (6) (2020)
Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas
Response to: 'Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus' by Wu et al. Annals of the rheumatic diseases (2020)
Antonis Fanouriakis, George Bertsias
Changing paradigms in the treatment of systemic lupus erythematosus. Lupus science & medicine 6 (1) (2019)
Christina Adamichou, Dionysis Nikolopoulos, Irini Genitsaridi, Alessandra Bortoluzzi, Antonis Fanouriakis, Emmanouil Papastefanakis, Eleni Kalogiannaki, Irini Gergianaki, Prodromos Sidiropoulos, Dimitrios T Boumpas, George K Bertsias
In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Annals of the rheumatic diseases 79 (2) (2019)
Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas
Hydroxychloroquine dosing in systemic lupus erythematosus: response to 'Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al' by Costedoat-Chalumeau et al. Annals of the rheumatic diseases 79 (8) (2019)
Antonis Fanouriakis, Myrto Kostopoulou, Alessia Alunno, Martin Aringer, Ingeborg Bajema, John N Boletis, Ricard Cervera, Andrea Doria, Caroline Gordon, Marcello Govoni, Frédéric Houssiau, David Jayne, Marios Kouloumas, Annegret Kuhn, Janni L Larsen, Kirsten Lerstrøm, Gabriella Moroni, Marta Mosca, Matthias Schneider, Josef S Smolen, Elisabet Svenungsson, Vladimir Tesar, Angela Tincani, Anne Troldborg, Ronald van Vollenhoven, Jörg Wenzel, George Bertsias, Dimitrios T Boumpas
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the rheumatic diseases 78 (6) (2019)
Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas
Response to: 'Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations' by Orsolini et al. Annals of the rheumatic diseases 79 (11) (2019)
Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas
Response to: 'Treatment of systemic lupus erythematosus: don't forget hydroxychloroquine' by Michaud et al. Annals of the rheumatic diseases 79 (10) (2019)
Antonis Fanouriakis, George K Bertsias, Dimitrios T Boumpas
Chloroquine as alternative antimalarial in systemic lupus erythematosus. Response to '2019 update of the EULAR recommendations for the management of SLE: don't forget chloroquine' by Figueroa-Parra et al. Annals of the rheumatic diseases 79 (9) (2019)
Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas
Response to: 'Concerns about the operational definition of remission in 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus' by Rua-Figueroa and Erausquin. Annals of the rheumatic diseases 79 (10) (2019)
Nikolaos I Panousis, George K Bertsias, Halit Ongen, Irini Gergianaki, Maria G G Tektonidou, Maria Trachana, Luciana Romano-Palumbo, Deborah Bielser, Cedric Howald, Cristina Pamfil, Antonis Fanouriakis, Despoina Kosmara, Argyro Repa, Prodromos Sidiropoulos, Emmanouil T Dermitzakis, Dimitrios T Boumpas
Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. Annals of the rheumatic diseases 78 (8) (2019)